Abstract:Objective: To compare the effects of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on hostility in first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder. Method: We used the data acquired in the European First-Episode Schizophrenia Trial, an open, randomized trial (conducted in 14 countries) comparing 5 antipsychotic drugs in 498 patients aged 18-40 years with first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder. DSM-IV diagnostic criteria were used. Patients were assessed between December 23, 2002 and January 14, 2006. Most subjects joined the study as inpatients and then continued with follow-ups in outpatient clinic visits. The Positive and Negative Syndrome Scale (PANSS) was administered at baseline and at 1, 3, 6, 9, and 12 months after randomization. We analyzed the scores on the PANSS hostility item in a subset of 302 patients showing at least minimal hostility (a score > 1) at baseline. We hypothesized (1) that the treatments would differ in their efficacy for hostility and (2) that olanzapine would be superior to haloperidol. Our primary statistical analysis tested the null hypothesis of no difference among the treatment groups in change in hostility over time. Secondary analysis addressed the question of whether the effects on hostility found in the primary analysis were specific to this item. All our analyses were post hoc. Results: The primary analysis of hostility indicated an effect of differences between treatments (F-4,F-889 = 4.02, P = .0031). Post hoc treatment-group contrasts for hostility change showed that, at months 1 and 3, olanzapine was significantly superior (P < .05) to haloperidol, quetiapine, and amisulpride in reducing hostility. Secondary analyses demonstrated that these results were at least partly specific to hostility. Conclusions: Both hypotheses were supported. Olanzapine appears to be a superior treatment for hostility in early phases of therapy for first-episode schizophrenia, schizoaffective disorder, and schizophreniform disorder. This efficacy advantage of olanzapine must be weighed against its adverse metabolic effects and propensity to cause weight gain. Trial Registration: ISRCTN Register Identifier: ISRCTN68736636 J Clin Psychiatry 2011;72(7):955-961 (C) Copyright 2011 Physicians Postgraduate Press, Inc.

Do Antipsychotics Affect Insight in Psychosis Differentially? Data from the EUFEST Trial.

Differential Effects of Antipsychotic Drugs on Insight in First Episode Schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST)

Eff Ectiveness of Antipsychotic Drugs in Fi Rst-Episode Schizophrenia and Schizophreniform Disorder : an Open Randomised Clinical Trial

Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).

Interpreting treatment trials in schizophrenia patients: lessons learned from EUFEST.

Psychotic Symptoms and Attitudes Toward Medication Mediate the Effect of Insight on Personal-Social Functions in Patients with Schizophrenia: One-Year Randomized Controlled Trial and Follow-Up

Short-term Effects of Antipsychotic Treatment on Cerebral Function in Drug-Naive First-Episode Schizophrenia Revealed by “resting State” Functional Magnetic Resonance Imaging

Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial

Insight and Prefrontal Cortex in First-Episode Schizophrenia

Extrapyramidal Symptoms During Treatment of First Schizophrenia Episode: Results from Eufest

Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments

Treatment of depression in first episode of schizophrenia: results from EUFEST.

Neurocognitive Effects of Atypical Antipsychotics in Patients with First-Episode Schizophrenia.

Effects Of Olanzapine, Quetiapine, And Risperidone On Neurocognitive Function In Early Psychosis: A Randomized, Double-Blind 52-Week Comparison

The European First Episode Schizophrenia Trial (EUFEST): Rationale and Design of the Trial

Neurocognitive Effects of First- and Second-Generation Antipsychotic Drugs in Early-Stage Schizophrenia: A Naturalistic 12-Month Follow-Up Study

Olanzapine and Haloperidol in First Episode Psychosis: Two-year Data

Psychiatrists effect on positive symptom severity and daily functioning during pharmacotherapy for first-episode psychosis patients

Metabolic Risk Factors In First-Episode Schizophrenia: Baseline Prevalence And Course Analysed From The European First-Episode Schizophrenia Trial

Long‐term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta‐analysis

Cognitive Effects of Atypical Antipsychotic Drugs in First-Episode Drug-Naïve Schizophrenic Patients.